Common themes that have kept me invested:

- we have a ten year lead over our competition in epigenetics

- our dual mechanism, anti viral and reduction of inflammation works on all Covid variants

- btd awarded to Apabetalone by fda

- Apabetalone is safe as proven in over 4000 man years of clinical testing

- the Star Factory 

- Zenith Epigenetics partnerships with BP and trial successes

- Covid ph3 trial with eua if successful

- BOMII trial with NDA upon successful interim analysis

- Eversana commercialization partnetship

- multi billion annual revenues if approved with lengthy patent lifes

- many potential uses for Apabetalone 

- the science

- potential of a BP buyout

- credible major shateholders

unfortunately there are growing negatives

- lack of reliable management communication to shareholders

- several clinical trial failures

- poor corporate management

- intellectual property encumbered

- no short or long-term financial plans

- growing debt and questionable ability to continue as going concern

- hepalink growing minority interest

- future revenue commitments of Apabetalone revenues to China, Israel, Eversana, Royalty Preferred Shares

- lack of BP interest 

- market value

- inability to recruit trial participants

lots of questions and concerns need to be addressed at the AGM

will we get answers?

Will we have a marketable product or is Apabetalone a failure?